Jupiter Life Line Hospitals DuPont analysis

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
0.74×0.75×0.75×0.90×0.57×
0.96×1.04×1.08×1.00×0.79×
16.0%17.0%19.0%18.3%18.2%
0.70×0.70×0.79×0.94×0.91×
1.57×1.54×1.40×1.10×2.71×
12.6%14.3%17.0%17.0%20.1%
13.4%13.4%15.3%23.1%20.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

JLHL₹260.10

Jupiter Life Line Hospitals Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPMAXHEALTHKIMSHCGMARKSANSMETROPOLISPARKHOSPSCORONAMcap ₹1,705 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.570.900.750.750.74
Interest Burden (Pretax/EBIT) ×0.791.001.081.040.96
EBIT Margin %18.2418.3118.9917.0415.97
Asset Turnover ×0.910.940.790.700.70
Financial Leverage (Assets/Equity) ×2.711.101.401.541.57
ROE (5-step product, year-end total equity) %20.1317.0217.0214.3412.55
ROE (owners' profit / average owners' equity) %20.0323.0515.3013.4113.41
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.